Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine, is pleased to announce another new contract win with a Top 10 Global Pharma Company.
Further to its announcement on 9 August 2024 of an agreement for a new contract with a major global pharmaceutical company with a value of at least US$1.5M, Oncimmune has now agreed a new project with another major pharmaceutical company, with the contract value of US$0.7m. The contract is with a customer for whom Oncimmune is already a preferred supplier under a long-term master services agreement. The project focuses on a rare immune related disease, an area in which Oncimmune has considerable experience, and aims to identify biomarkers related to disease or disease subtype, organ involvement and clinical response. It will use an array of over 1,000 antigens run on Oncimmune’s high-throughput, bead-based system. Oncimmune will analyse over 500 samples, many of which are already held by Oncimmune.
Martin Gouldstone, CEO of Oncimmune said: “I continue to be pleased with the commercial progress we are making, especially in terms of the increasing scale of the projects we are winning with major customers. Our recent wins show that our strategy is working and I am confident that we are in a strong position to meet our targets for FY24 and reach profitability in FY25.”
For further information contact:
Oncimmune Holdings plc